(Supplementary Fig.3a), as well as A20 tumors in which case a proportion of mice rejected the tumors completely (11/30), reflecting the enhanced immunogenicity of A20 compared to 4T1 tumor (Fig.3c). The generality of inducing new antigens by targeting key mediators of antigen processing is...
Since HN-1 is a targeting peptide for squamous cell carcinoma and normal epithelial cells HOK, the targeted internalization of drugs is not accelerated by the nanocarrier NGO-PEG-HN-1, and the pH environment of normal cells is not conducive to drug release. Furthermore, HN-1 possesses strong...
在健康组织中,Probody抗体基本上保持完整,Masking peptide阻止了抗体和靶点结合,避免了off-tumor的副作用。当Probody到达肿瘤微环境,肿瘤相关蛋白酶切割底物linker,去除掩蔽肽,抗体结合靶抗原。 基于Probody技术抗体药物开发CX-072(靶点PD-L1) CX-072是基于Probody技术的早期项目。2017年开展临床研究PROCLAIM-CX-072(PRObo...
抗肿瘤单克隆IgG抗体或可变区域的片段, 与轻链的N端相连的掩蔽肽(Masking peptide), 可切割的linker的蛋白酶 在健康组织中,Probody抗体基本上保持完整,Masking peptide阻止了抗体和靶点结合,避免了off-tumor的副作用。当Probody到达肿瘤微环境,肿...
Recently, Prof. Qian Zhiyong’s team of the State Key Laboratory of Biotherapy, WCH, published an online research paper titled “Tumor microenvironment responsive drug-dye-peptide nanoassembly for enhanced tumor-targeting, penetration, and photo-chemo-immunotherapy”in a well-known journal in the fiel...
Furthermore, R11 peptides formed hydrogen bonds with integrin 尾1, facilitating targeting and penetration into tumor cells. Additionally, R11 peptides protected integrin 尾1 from lysosome degradation, promoting its recycling from cytoplasm to membrane. Moreover, this findings establish a...
Explore tumor antigen-derived peptides for cancer immunotherapy, vaccine development, and antigen targeting.
targeting therapies are particularly of significance in anti-cancer strategies. The application of TAMs as anti-cancer targets is expected to break through traditional tumor-associated therapies and achieves favorable clinical effect. However, the heterogeneity of TAMs makes the strategy of targeting TAMs...
Trabid targeting sensitizes tumor response to anti-PD-1 therapy The enhancement of intratumoral infiltration of anti-tumor immune cells by Trabid depletion suggests that Trabid targeting could shape a “hot” TME to improve tumor response to ICB therapy. Furthermore, the upregulation of PD-L1 by...
For evaluation of systemic tumor homing of the candidate TNC-C-targeting peptides, we usedin vivophage play-off auditioning22. Tumor-bearing mice were injected i.v. with a phage pool of equally represented candidate TNC-C binding and control phages, followed by circulation, perfusion, and asses...